Question explored with the scientific record
Conversation so far
- 1 treatment for ocular melanoma eye tumour
- 2 what are the chances of cancer spreading to liver after radioactive seedd sewn onto eye
- 3 will radioactive seed treatment save sight?
- 4 basic advice: eye removal versus radioactive seed?
- 5 Do eye hospitals recommend radioactive seed because they want patients to practise this on?
- 6 What ongoing treatment will be needed after radioctive seed treatment?
- 7 Will I be able to drive again following radioactive seed?
Answered on this page ↓
Will I be able to drive again following radioactive seed?
The short version: driving is a vision question, not a radiation-safety question, and the records here don't give a driving rule.
The seeds are placed on the eye and removed after a few days, so the practical limit on driving is your eyesight, not the radiation itself. The records show why eyesight is at risk. In one 82-patient series, about 26 in 100 lost visual acuity [4]. In a 190-patient iodine-125 series, higher doses tracked with more vision loss and more radiation complications [5]. A 42-patient ciliary body series found 24% radiation retinopathy and 55% cataract [1]. A 30-patient brachytherapy group had 59% radiation retinopathy and 62% cataract [3]. In a 2026 paediatric series, one iodine-125 case ended at 6/36 vision and a ruthenium case at 6/30 [2].
| Series | Vision outcome |
|---|---|
| 82 patients, Eye Physics plaques [4] | 25.6% lost acuity |
| 190 patients, iodine-125 [5] | Higher dose, more vision loss |
| 30 patients, brachytherapy [3] | 59% retinopathy, 62% cataract |
| Paediatric iodine-125 case [2] | 6/36 at 18 months |
None of these records states a driving standard, a waiting period, or a legal vision threshold. That is a gap in this retrieval, not a finding. In general practice, outside these records, driving rules are set by your licensing authority and depend on measured acuity and visual field in the treated eye and the good eye. Ask your ophthalmologist to test both and to say plainly whether you meet the standard.
My call: you can likely drive again if your good eye and visual field meet your licensing standard, but the records cannot promise it, and the treated eye alone may not qualify. Confidence: low, because no retrieved study measured driving.
Sources used 5
-
Management of ciliary body melanoma with iodine-125 plaque brachytherapy
A retrospective, nonrandomized case series evaluating presentation, management, and outcomes of 42 patients with ciliary body melanoma treated with iodine-125 plaque brachytherapy, showing high tumor control and eye preservation but notable radiation-related ocular morbidity.
DOI: 10.3129/i09-097 -
Paediatric uveal melanoma in Ireland 2010 – 2024: incidence, clinical features, management, and outcomes
Paediatric uveal melanoma in Ireland (2010–2024) comprises six cases at a single national centre, treated with enucleation or radiotherapy, with generally favorable outcomes and no metastases during follow-up, underscoring the need for international data to clarify incidence tre…
DOI: 10.1038/s41433-026-04334-2 -
A comparison between 125 Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma
This study compares the treatment efficacy and radiation complications of 125 Iodine brachytherapy and stereotactic radiotherapy in managing juxtapapillary choroidal melanoma, finding comparable efficacy but higher radiation-induced ocular morbidities with stereotactic radiother…
DOI: 10.1136/bjophthalmol-2012-302808 -
Outcomes of Choroidal Melanomas Treated With Eye Physics
This study reviews the outcomes of 82 patients treated for medium-sized choroidal melanoma using Eye Physics plaques and compares these results with the Collaborative Ocular Melanoma Study, finding favorable rates of local control and fewer adverse effects.
DOI: 10.1001/jamaophthalmol.2013.4422 -
Uveal Melanoma Treated With Iodine-125 Episcleral Plaque: An Analysis of Dose on Disease Control and Visual Outcomes
This retrospective study of 190 patients with uveal melanoma treated with iodine-125 plaque brachytherapy found that while increasing radiation doses correlated with greater visual acuity loss and radiation complications, they did not affect tumor control outcomes.
DOI: 10.1016/j.ijrobp.2014.01.026